BR0013664A - Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa - Google Patents

Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa

Info

Publication number
BR0013664A
BR0013664A BR0013664-6A BR0013664A BR0013664A BR 0013664 A BR0013664 A BR 0013664A BR 0013664 A BR0013664 A BR 0013664A BR 0013664 A BR0013664 A BR 0013664A
Authority
BR
Brazil
Prior art keywords
compound
gabaa
agonism
inverted
gaba
Prior art date
Application number
BR0013664-6A
Other languages
English (en)
Inventor
Pamela Albaugh
Kenneth Shaw
Alan Hutchison
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of BR0013664A publication Critical patent/BR0013664A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K51/047—Benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Abstract

"COMPOSTO, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA O TRATAMENTO DE UMA DOENçA OU DISTúRBIO ASSOCIADO COM AGONISMO PATOGêNICO, AGONISMO INVERTIDO OU ANTAGONISMO DO RECEPTOR DE GABA~ A~, PARA LOCALIZAR OS RECEPTORES DE GABA~ A~, PARA INIBIR A LIGAçãO DE UM COMPOSTO DE BENZODIAZEPINA A UM RECEPTOR DE GABA~ A~, E PARA ALTERAR A ATIVIDADE DE TRANSDUçãO DE SINAL DE RECEPTORES GABA~ A~". Compostos de pirrolcarboxamida substituída são apresentados. Estes compostos são agonistas, antagonistas ou agonistas invertidos altamente seletivos para receptores do cérebro de GABA~ A~ ou pró-medicamentos de agonistas, antagonistas ou agonistas invertidos para receptores do cérebro de GABA~ A~ e são por esse motivo úteis no diagnóstico e tratamento de ansiedade, depressão, demência de Alzheimer, distúrbios do sono e convulsão, dose excessiva com drogas de benzodiazepina e para o aumento da memória. Composições farmacêuticas, incluindo composições farmacêuticas embaladas, são ainda fornecidas. Os compostos da invenção são também úteis como sondas para a localização de receptores de GABA~ A~ em amostras de tecido.
BR0013664-6A 1999-08-31 2000-08-30 Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa BR0013664A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15178999P 1999-08-31 1999-08-31
US38731199A 1999-08-31 1999-08-31
PCT/US2000/023862 WO2001016103A1 (en) 1999-08-31 2000-08-30 Fused pyrrolecarboxamides: gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
BR0013664A true BR0013664A (pt) 2002-05-14

Family

ID=26848974

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013664-6A BR0013664A (pt) 1999-08-31 2000-08-30 Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa

Country Status (25)

Country Link
US (1) US7109351B1 (pt)
EP (1) EP1210328A1 (pt)
JP (1) JP2003508385A (pt)
KR (1) KR20020027613A (pt)
CN (1) CN1372546A (pt)
AP (1) AP2002002420A0 (pt)
AU (1) AU7092800A (pt)
BG (1) BG106459A (pt)
BR (1) BR0013664A (pt)
CA (1) CA2381553A1 (pt)
CR (1) CR6581A (pt)
CZ (1) CZ2002614A3 (pt)
EA (1) EA200200188A1 (pt)
EE (1) EE200200111A (pt)
HR (1) HRP20020104A2 (pt)
HU (1) HUP0202534A3 (pt)
IL (1) IL147971A0 (pt)
IS (1) IS6290A (pt)
MX (1) MXPA02001709A (pt)
NO (1) NO20020948L (pt)
OA (1) OA12015A (pt)
PL (1) PL354513A1 (pt)
SK (1) SK2582002A3 (pt)
TR (1) TR200200544T2 (pt)
WO (1) WO2001016103A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014939A1 (en) * 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
EP1265857A1 (en) * 2000-03-13 2002-12-18 Eli Lilly And Company Sulfonamide derivatives
WO2001092257A1 (en) * 2000-05-26 2001-12-06 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US6656941B2 (en) 2000-09-06 2003-12-02 Neurogen Corporation Aryl substituted tetrahydroindazoles
JP2004508352A (ja) 2000-09-06 2004-03-18 ニューロゲン　コーポレイション 置換縮合ピロールイミン及びピラゾールイミン
US6861529B2 (en) * 2001-07-06 2005-03-01 Pfizer Inc Cycloalkypyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives
JP2005525333A (ja) 2002-02-07 2005-08-25 ニューロジェン コーポレイション 置換縮合ピラゾールカルボン酸アリールアミド及び関連化合物
AU2004265189B2 (en) * 2003-08-15 2010-03-04 Banyu Pharmaceutical Co., Ltd. Imidazopyridine derivatives
CA2580730C (en) 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
AU2005240942B2 (en) * 2004-05-10 2010-08-05 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
US20080275112A1 (en) * 2004-07-23 2008-11-06 Schreiner Peter R Invention Concerning Aminoadamantane Compounds
JP2010510987A (ja) * 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
CA2707492A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455943A (en) 1966-10-21 1969-07-15 American Cyanamid Co Certain 5,8-dihydro-beta-carbolines
US4075343A (en) 1976-09-13 1978-02-21 Pfizer Inc. Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
DE3029980A1 (de) 1980-08-08 1982-03-11 Boehringer Mannheim Gmbh, 6800 Mannheim Indolderivate und verfahren zu ihrer herstellung
JPS57123180A (en) 1980-12-17 1982-07-31 Schering Ag 3-substituted beta-carboline, manufacture and psychotropic drug containing same
DE3147276A1 (de) 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
DE3246932A1 (de) 1982-12-16 1984-06-20 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte 5h-pyrimido(5,4-b)indole
DE3335323A1 (de) 1983-09-27 1985-04-04 Schering AG, 1000 Berlin und 4709 Bergkamen Substituierte ss-carboline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8429739D0 (en) 1984-11-24 1985-01-03 Fbc Ltd Fungicides
DE3535927A1 (de) 1985-10-04 1987-04-09 Schering Ag 3-vinyl- und 3-ethinyl-ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel
DK0552237T3 (da) 1990-10-09 1993-07-28 Neurogen Corp Visse cycloalkyl- og azacycloalkyl-pyrrolopyrimidiner, en klasse af ligander for GABA-receptorer i hjernen
US5243049A (en) 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
AU3443493A (en) 1992-02-19 1993-09-13 Upjohn Company, The 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
AU6098194A (en) 1993-01-29 1994-08-15 Ariad Pharmaceuticals, Inc. Analogs of receptor tyrosine activation motifs and therapeutic uses thereof
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US5804686A (en) 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
IT1287264B1 (it) * 1996-03-21 1998-08-04 Lino Crespan Freno perfezionato per pattini con ruote in linea
WO1997034870A1 (en) 1996-03-22 1997-09-25 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
US5955465A (en) 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
US5723462A (en) 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
AU745788B2 (en) 1997-11-13 2002-03-28 Pfizer Products Inc. Method of synthesis of pyrrole amides

Also Published As

Publication number Publication date
NO20020948L (no) 2002-02-28
HUP0202534A3 (en) 2002-12-28
EE200200111A (et) 2003-06-16
EP1210328A1 (en) 2002-06-05
AU7092800A (en) 2001-03-26
KR20020027613A (ko) 2002-04-13
IL147971A0 (en) 2002-09-12
CZ2002614A3 (cs) 2002-08-14
CR6581A (es) 2004-03-31
SK2582002A3 (en) 2003-02-04
PL354513A1 (en) 2004-01-26
NO20020948D0 (no) 2002-02-27
CA2381553A1 (en) 2001-03-08
AP2002002420A0 (en) 2002-03-31
MXPA02001709A (es) 2002-10-23
TR200200544T2 (tr) 2002-06-21
HUP0202534A2 (hu) 2002-11-28
EA200200188A1 (ru) 2002-08-29
IS6290A (is) 2002-02-27
BG106459A (bg) 2002-12-29
HRP20020104A2 (en) 2004-02-29
CN1372546A (zh) 2002-10-02
US7109351B1 (en) 2006-09-19
JP2003508385A (ja) 2003-03-04
OA12015A (en) 2006-04-19
WO2001016103A1 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
BR0010308A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
BR0113300A (pt) Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, método para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, uso de um composto ou um sal, é, métodos para localização dos receptores de gabaa em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina a um receptor de gabaa, e para a alteração da atividade de transdutora de sinal dos receptores de gabaa
BR0013664A (pt) Composto, uso de um composto, composição farmacêutica, e, métodos para o tratamento de uma doença ou distúrbio associado com agonismo patogênico, agonismo invertido ou antagonismo do receptor de gabaa, para localizar os receptores de gabaa, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, e para alterar a atividade de transdução de sinal de receptores gabaa
Carlsson et al. Network interactions in schizophrenia—therapeutic implications
Paolone et al. Eltoprazine prevents levodopa‐induced dyskinesias by reducing striatal glutamate and direct pathway activity
Amargós-Bosch et al. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine
WO2002000623A3 (en) Aryl fused substituted 4-oxy-pyridines
BR0015420A (pt) Composto, composição farmacêutica, métodos de tratamento de uma doença ou de um distúrbio associados com agonismo patogênio, para a localização de receptores gabaa, em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina em um receptor gabaa, e de alteração da atividade de transdução de sinal de receptores gabaa, agonismo inverso ou antagonismo do receptor gabaa, uso de um composto, e , composição faramcêutica embalada
Lagos et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats
Lesch et al. 5-HT 1A receptor function in depression: effect of chronic amitriptyline treatment
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
BRPI0417323A (pt) indóis, 1h-indazóis, 1,2-benzisoxazóis, e 1,2-benzisotiazóis, composto, composição farmacêutica e usos dos mesmos
CA2246839A1 (en) Pharmaceutical compositions containing ampa receptor antagonists for treating dyskineslas associated with dopamine agonist therapy
BRPI0413342A (pt) composto, composição farmacêutica, métodos para aumentar seletivamente a ativação do receptor de 5-ht2c em mamìferos, para tratar obesidade em mamìferos, para tratar distúrbios obsessivo/compulsivo em mamìferos, para tratar depressão em mamìferos e para tratar ansiedade em mamìferos, e, uso de um composto
BR0211124A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para alterar a atividade de transdução de sinal de receptores gabaa, para o tratamento de ansiedade, depressão, distúrbio do sono, esquizofrenia, distúrbio de hiperatividade-falta de atenção, ou para a melhora de memória, e para demonstrar a presença de receptores gabaa em uma célula ou amostra de tecido, composição farmacêutica embalada, e, uso de um composto ou sal
BR0108025A (pt) Compostos de amida, sal farmaceuticamente aceitável de um metabólito farmaceuticamente ativo do composto, composição farmacêutica para modular ou inibir a atividade de um receptor de proteìna cinase, método de tratamento de uma condição doentia de mamìferos mediada pela atividade de proteìna cinase e método para modular ou inibir a atividade de um receptor de proteìna cinase
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
WO2000077008A3 (en) Heteroaryl substituted piperidines as gaba brain receptor lingands
Pockros et al. 5‐HT2A receptor blockade and 5‐HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate‐putamen
BR0307504A (pt) Composto ou sal farmaceuticamente aceitável, composição farmacêutica, métodos tratar doenças, para potencializar um efeito terapêutico de um agente para o snc, para melhorar a memória de curto prazo em um paciente, para determinar a presença ou ausência de receptores gabaa em uma amostra, e para alterar a atividade transdutora de sinal do receptor gabaa, embalagem, e, uso de um composto ou sal
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
Sills et al. The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat
BRPI0409570A (pt) derivados de 3-benzidrilideno-8-aza-biciclo[3.2.1]octano com atividade receptora de opióides
BR0113696A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou sal, e, métodos para tratar de uma doença ou distúrbio associados com o agonismo patogênico, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa, para alterar a atividade transdutora de sinal dos receptores de gabaa e para preparar um composto
Kasahara et al. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]